Dr. Jagannath On Next-Generation Approaches In Multiple Myeloma

Dr. Jagannath on Next-Generation Approaches in Multiple Myeloma

Dr. Jagannath on Potential of Immunotherapy in Multiple Myeloma

Dr. Jagannath on Immunotherapy in Multiple Myeloma

Dr. Jagannath on the Importance of Biology in Multiple Myeloma

Development of a novel next generation myeloma-specific liquid biopsy approach

VJHemOnc – Video Journal of Hematology & HemOnc

Dr. Jagannath on Targeted Therapies and Stem Cell Transplantation in Multiple Myeloma

Targeted Oncology

Dr. Sundar Jagannath on Significant Studies in Multiple Myeloma

How next-generation sequencing will change the treatment of multiple myeloma

VJHemOnc – Video Journal of Hematology & HemOnc

Dr. Jagannath Discusses the VANTAGE Trials

Dr. Jagannath on CAR T-Cell Therapy for Multiple Myeloma

Dr. Sundar Jagannath on Three-Drug Regimen for Newly Diagnosed Multiple Myeloma

Dr. Jagannath on Sequencing Therapies for Patients With Multiple Myeloma

Dr. Bustoros on Next-Generation Sequencing in Multiple Myeloma

Dr.Jagannath on Role for Two-Drug Combinations, Carfilzomib Triplet in Multiple Myeloma

Dr. Jagannath Discusses Advances in the Management of Relapsed Multiple Myeloma

Targeted Oncology

Dr. Sundar Jagannath Discusses the Approval of Lenalidomide in Multiple Myeloma

Future Directions for Novel and Next Generation Therapy in Multiple Myeloma | Dana-Farber

Dana-Farber Cancer Institute

The utility of next-generation sequencing for multiple myeloma

VJHemOnc – Video Journal of Hematology & HemOnc

Current and Future Directions for Novel Therapy for Multiple Myeloma: Paul G. Richardson, MD

Dana-Farber Cancer Institute

Dr. Jagannath on the Safety Profile of Selinexor in Multiple Myeloma